Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

(2014) T. Placke et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

HighEVI1expression is associated withMLLrearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group

(2013) Phoenix A. Ho et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB

(2013) Hsu-Ping Kuo et al.   CANCER CELL

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML

(2013) K R Kampen et al.   LEUKEMIA

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia

(2013) V Grossmann et al.   LEUKEMIA

In Vivo Imaging Enables High Resolution Preclinical Trials on Patients’ Leukemia Cells Growing in Mice

(2013) Nadia Terziyska et al.   PLoS One

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases

(2012) Harald Polzer et al.   EXPERIMENTAL HEMATOLOGY

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing

(2012) D. C. Koboldt et al.   GENOME RESEARCH

Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens

(2012) Satoko Yamamoto et al.   Breast Cancer

Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule

(2011) H. Ehrhardt et al.   BLOOD

Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins

(2011) A. Yoshimi et al.   BLOOD

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

(2009) K. Ye et al.   BIOINFORMATICS

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients

(2009) Folkward G. Wiesner et al.   BREAST

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells

(2009) Andrew L. Muranyi et al.   EXPERIMENTAL HEMATOLOGY

Targeted therapy in acute myeloid leukaemia: current status and future directions

(2009) Camilla Stapnes et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated

(2008) S. Lugthart et al.   BLOOD

Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells

(2008) Katharina Salome Minke et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia

(2008) Sampa Ghoshal (Gupta) et al.   LEUKEMIA RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer

(2008) B. A. Rabinovich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA